Engineered E. coli Boosts Microcin J25 Production by Overcoming Inhibitors
Background
Microcin J25 (MccJ25) is a promising antimicrobial peptide with potential applications against Gram-negative bacteria, offering a novel approach to combat antimicrobial resistance. However, its industrial production is hampered by low yields due to complex regulatory mechanisms and environmental factors. This study aimed to overcome the challenges of growth phase dependency and metal ion inhibition that limit high-yield biosynthesis of MccJ25 in Escherichia coli.
Results
The dual engineering strategy significantly enhanced Microcin J25 production, demonstrating a robust and efficient biosynthesis platform. The engineered E. coli strain achieved a remarkable 2.5-fold increase in MccJ25 yield compared to the wild-type strain, showcasing the effectiveness of the combined approach. Production was sustained for over 72 hours, demonstrating successful decoupling from the growth phase and enabling prolonged synthesis. This sustained, high-level production was achieved without compromising the inherent antimicrobial activity of the peptide. The optimized system resulted in a peak MccJ25 titer of 125 mg/L, representing a 3.8-fold improvement over previous methods and a 90% reduction in sensitivity to inhibitory metal ions.
Why It Matters
This dual engineering approach provides a robust platform for the cost-effective, high-yield biosynthesis of Microcin J25, making it more accessible for research and potential therapeutic development. The ability to produce MccJ25 efficiently could accelerate its evaluation as a novel antibiotic alternative in an era of increasing antimicrobial resistance, addressing a critical global health challenge. This advancement could pave the way for industrial-scale production, potentially leading to new clinical applications for this potent antimicrobial peptide. Further research will focus on scaling up this process in bioreactors and testing MccJ25's efficacy in preclinical infection models.